Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $61.11 Average Target Price from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $61.11.

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Piper Sandler increased their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Morgan Stanley lifted their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 60,000 shares of company stock valued at $3,425,000 over the last ninety days. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Verdence Capital Advisors LLC grew its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares during the period. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the last quarter. Fifth Third Bancorp raised its position in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 261 shares during the period. Private Advisor Group LLC boosted its stake in Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 412 shares during the last quarter. Finally, Juncture Wealth Strategies LLC grew its position in shares of Halozyme Therapeutics by 3.6% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 415 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 1.4 %

Halozyme Therapeutics stock opened at $48.47 on Friday. The company has a market capitalization of $6.17 billion, a PE ratio of 16.05, a PEG ratio of 0.43 and a beta of 1.29. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The firm’s fifty day moving average is $53.72 and its 200 day moving average is $53.67. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.